Latest Breaking News On - கிரெக் மரோஸ் - Page 1 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. CytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral Sclerosis May 7, 2021 GMT LOS ANGELES (BUSINESS WIRE) May 7, 2021 CytRx Corporation (OTCQB: CYTR) (“CytRx”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) (“Orphazyme”) announced that the ORARIALS-01 pivotal trial for arimoclomol in Amyotrophic Lateral Sclerosis (“ALS”) did not meet primary and secondary endpoints to show benefit in people living with the disease. According to Orphazyme, no important safety signals were reported in the trial. Topline data will be presented at the upcoming virtual European Network to Cure ALS meeting and complete data from the study will be published later this year.

United statesGreg marose bela kirpalaniEuropean network to cureCommittee for medicinal products humanCytrx corporationEuropean medicines agencyDrug administrationAmyotrophic lateral sclerosisEuropean networkNorth americaRating scale revisedMedicinal productsHuman useNasdaq copenhagenGreg maroseBusiness wire